Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis: Focus on Critically Ill Patients

Author： Reboli Annette C.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.8, 2011-08, pp. : 705-717

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anidulafungin cost effective for candidaemia and candidiasis

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Management of Invasive Candidiasis in Critically Ill Patients

By Stijn Blot   Koenraad Vandewoude  

Drugs, Vol. 64, Iss. 19, 2004-01 ,pp. : 2159-2175

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of fluconazole in critically ill patients

By Sinnollareddy Mahipal   Peake Sandra L   Roberts Michael S   Playford E Geoffrey   Lipman Jeffrey   Roberts Jason A  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1431-1440

Informa Healthcare

Access to resources Recommend Favorite

Micafungin appears to be cost saving versus caspofungin when used to treat candidaemia and invasive candidiasis

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 589, 2009-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients

By Fisher Brian T.   Zaoutis Theoklis E.  

Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. : 281-298

Adis International

Access to resources Recommend Favorite